LRRC51 Inhibitors
LRRC51 inhibitors are chemical compounds that indirectly decrease the functional activity of LRRC51 by targeting various signaling pathways or cellular processes that LRRC51 may depend on. Staurosporine, a broad-spectrum kinase inhibitor, can impede the activation of multiple kinases necessary for LRRC51-associated pathways. By inhibiting protein kinase C (PKC), staurosporine might decrease the phosphorylation and subsequent activation of downstream targets that are crucial for LRRC51 activity or stability. Similarly, LY294002, a PI3K inhibitor, suppresses the PI3K/AKT pathway, which is pivotal for cell survival and proliferation. Since LRRC51 may rely on AKT-mediated signals for its functional activity, inhibiting PI3K can attenuate LRRC51 activity indirectly.
Another approach to inhibit LRRC51 is through the interruption of the MAPK pathway. PD98059 and U0126 are specific inhibitors of MEK1/2, which are central components of the MAPK pathway. By blocking MEK1/2, these inhibitors prevent the activation of ERK1/2, which are downstream kinases in the pathway. This leads to reduced transcriptional activity of genes that may be critical for LRRC51 function. Consequently, without the necessary signals from the MAPK pathway, LRRC51's activity could be diminished, representing an indirect form of inhibition.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a potent protein kinase C (PKC) inhibitor which can lead to a downstream inhibition of various pathways that promote cell survival and proliferation. Inhibition of PKC may subsequently decrease the functional activity of LRRC51 by reducing cellular signaling that LRRC51 relies on for its activation or stabilization. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a phosphatidylinositol 3-kinase (PI3K) inhibitor that prevents phosphorylation of AKT, leading to the inhibition of the PI3K/AKT pathway. Since LRRC51 function might be dependent on AKT-mediated signals for stability or activity, LY294002 can indirectly diminish the activity of LRRC51. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 specifically inhibits p38 MAP kinase, which is involved in stress and inflammatory responses. Inhibition of p38 MAPK could reduce the activation of transcription factors or other proteins that may upregulate the expression or enhance the activity of LRRC51, thus leading to its functional inhibition. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits the mammalian target of rapamycin (mTOR), a key regulator of cell growth and proliferation. By inhibiting mTOR, rapamycin can decrease the translation of mRNA transcripts that are necessary for LRRC51 function or expression, indirectly inhibiting LRRC51. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a selective inhibitor of mitogen-activated protein kinase kinase (MEK), which interrupts the MEK/ERK pathway. This pathway's interruption can lead to the inhibition of cellular growth signals that may be necessary for the proper function or regulation of LRRC51. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is another MEK inhibitor, which also impedes the MEK/ERK pathway. By inhibiting this pathway, U0126 may prevent the activation of transcription factors or other signaling molecules that could be important for LRRC51 activity, thereby indirectly inhibiting LRRC51. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK), which is part of a signaling pathway that affects cell survival, apoptosis, and differentiation. LRRC51, if involved in these processes, might be affected by JNK inhibition, as the pathway's suppression could lead to a decrease in LRRC51 activity. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent inhibitor of PI3K like LY294002. It also prevents the activation of AKT, which can lead to decreased cellular proliferation and survival signals that may be necessary for LRRC51's functional activity, resulting in its indirect inhibition. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
Imatinib is a tyrosine kinase inhibitor, primarily targeting BCR-ABL, c-KIT, and PDGFR. Tyrosine kinases are crucial for various cellular processes, including the activation of proteins. Inhibition of these kinases can indirectly inhibit LRRC51 if it is downstream of these signaling pathways. | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $420.00 | 32 | |
Lapatinib is a dual tyrosine kinase inhibitor, targeting HER2 and EGFR, which are involved in cell proliferation and survival. By inhibiting these receptors, lapatinib may reduce signals that would typically enhance the functional activity of LRRC51, leading to its inhibition. | ||||||